GIPR and type 2 diabetes mellitus: Both GLP-1 receptor agonists and DPP-IV inhibitors improve β-cell function and glycemic control in patients with type 2 diabetes [18], but there is controversy regarding the anti-diabetic potential for GIP receptor (GIPR) agonists [12].